Addex Therapeutics (APE) Notes NTX-253 Phase 1 Completion; Phase 2 Planned

Addex Therapeutics Ltd. (ADXN) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 ​ ​ ​ PRESS RELEASE ​ Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical co

Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.

JP Morgan increased its price target for Equinor to 400 NOK (360 USD) but maintained an underweight rating. Equinor's stock has seen a 5-day change of 403.50 NOK, a 1st Jan change of -1.59%, and a 1-year change of +70.25%.

argenx reported positive Phase 2 results for FB102 in celiac disease, meeting the primary endpoint. The company plans to advance to Phase 3. According to the company, no new safety signals were observed.

argenx SE (ARGX) will halt its Phase 3 UNITY trial of efgartigimod SC in Sjögren's disease due to futility, following an IDMC recommendation. The company reports safety data were consistent with prior findings. This marks a setback in argenx's efforts to expand the drug's use in autoimmune diseases.

argenx reported positive Phase 2 results for FB102, a CD122 inhibitor, in celiac disease. The study met its primary endpoint (p=0.0176) and showed efficacy across multiple measures. The company plans to advance FB102 into Phase 3 development. FB102 is also being evaluated for other autoimmune diseases.